Despite the significant improvements in the outcome of breast cancer that is ER-positive following letrozole treatment, a significant percentage (ranging from 30% to 65%) of patients either do not respond to aromatase inhibitors [1] or develop resistance and relapse after continued use [2,3,4]. This evidence concerns the gene CYP19A1 and breast carcinoma.